Alternatives to tofacitinib

How to Read These JAK Inhibitor Alternatives

tofacitinib (marketed as Xeljanz) sits within the JAK Inhibitor class, and the 2 alternatives above share the same therapeutic classification under FDA labeling. Drugs grouped this way typically work through similar mechanisms, but they are not interchangeable — each has its own pharmacokinetics, dosing schedule, contraindications, and adverse-event profile derived from separate clinical trials. The labeled indication for tofacitinib focuses on: Xeljanz treats rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis in adults.

The side-effect comparison above draws on FDA FAERS data, where tofacitinib has 198,395 reports across its top 10 reactions, measured against baricitinib, upadacitinib. Raw report counts reflect total exposure — a medication prescribed to tens of millions will accumulate more reports than a newer or niche option even when per-patient risk is lower. Dashes in the comparison table mean that reaction was not among the top reported events for that drug, not that it never occurs. Generic availability for tofacitinib is well established, and competing products often have substantially different acquisition costs under NADAC.

Switching between medications in the same class is a clinical decision with real consequences — dosing conversions are not one-to-one, interaction profiles differ, and prior treatment response is individual. Shortage status, insurance formulary placement, and out-of-pocket cost all influence which alternative is practical in a given situation. This comparison surfaces public FDA data to help patients and caregivers prepare informed questions; it is for educational purposes only and does not constitute medical advice. Always talk to your prescriber or pharmacist before switching or stopping any medication.